Home » Stocks » Athira Pharma

Athira Pharma, Inc. (ATHA)

Stock Price: $20.98 USD -0.10 (-0.47%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 646.59M
Revenue (ttm) n/a
Net Income (ttm) -6.30M
Shares Out 28.81M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $20.98
Previous Close $21.08
Change ($) -0.10
Change (%) -0.47%
Day's Open 21.07
Day's Range 20.51 - 22.14
Day's Volume 280,834
52-Week Range 15.79 - 22.14

More Stats

Market Cap 646.59M
Enterprise Value 561.42M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 28.81M
Float 29.11M
EPS (basic) n/a
EPS (diluted) -0.22
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 475,197
Short Ratio 0.86
Short % of Float 1.63%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 7.06
Revenue n/a
Operating Income n/a
Net Income -6.30M
Free Cash Flow n/a
Net Cash 85.17M
Net Cash / Share 2.76
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(102.57% upside)
Current: $20.98
Target: 42.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-5.45-5.01
Net Income-5.16-5.10
Shares Outstanding3.573.47
Earnings Per Share-1.45-1.47
Operating Cash Flow-3.71-4.48
Free Cash Flow-3.71-4.48
Cash & Equivalents2.064.82
Total Debt1.550.72
Net Cash / Debt0.514.10
Book Value-19.72-14.89
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Athira Pharma, Inc.
Country United States
Employees 14
CEO Leen Kawas

Stock Information

Ticker Symbol ATHA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ATHA
IPO Date September 18, 2020


Athira Pharma, a clinical-stage biopharmaceutical company, develops small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. The company also develops product candidates, which are in preclinical stage, including ATH-1019 for depression; and ATH-1018 for peripheral neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is based in Seattle, Washington.